No Data
No Data
No Data
No Data
No Data
中國抗體-B:年度報告2023
Futu NewsApr 26 16:31 · Announcements
China Antibody-B (03681) released annual results, achieving revenue of 1.3665 million yuan, and all businesses achieved expected performance
China Antibody-B (03681) announced its annual results for the year ended December 31, 2023, and the group achieved revenue...
Zhitong FinanceMar 25 21:45
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023; CHANGE IN USE OF PROCEEDS; PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; AND PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT
Futu NewsMar 25 21:38 · Announcements
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
券商中國Mar 13 21:18
China Antibody-B (03681.HK) plans to hold a board meeting on March 25 to consider and approve annual results
Gelonghui March 12 | China Antibody-B (03681.HK) announced that a board meeting will be held on March 25, 2024 (Monday) to consider and approve the Group's annual results and announcements for the year ended December 31, 2023, and to deal with other matters.
Gelonghui FinanceMar 12 18:29
SINOMAB BIO-B: DATE OF BOARD MEETING
Futu NewsMar 12 18:27 · Announcements
No Data
No Data